Update on bacterial meningitis: Epidemiology, trials and genetic association studies

Current Opinion in Neurology

Volumn 26, Issue 3, 2013, Pages 282-288

  Soemirien Kasanmoentalib, E ^a   Brouwer, Matthijs C ^a   Van De Beek, Diederik ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

adjuvant therapy; antibiotics; bacterial meningitis; genetics; randomized controlled trials; vaccination

Indexed keywords

CEFOTAXIME; CEFTRIAXONE; DEXAMETHASONE; GENTAMICIN; GLYCEROL; PARACETAMOL; PENICILLIN DERIVATIVE;

ANTIBIOTIC THERAPY; BACTERIAL MENINGITIS; BODY TEMPERATURE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HAEMOPHILUS INFLUENZAE; HEALTH CARE DELIVERY; HUMAN; HYPOTHERMIA; INCIDENCE; MORTALITY; NEISSERIA MENINGITIDIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; GENETIC ASSOCIATION STUDIES; HUMANS; MENINGITIS, BACTERIAL; VACCINATION; VACCINES, CONJUGATE;

EID: 84877715908     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328360415c     Document Type: Review

References (72)

1. van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med 2006; 354:44-53. (Pubitemid 43048950)
2. Hoogman M, van de Beek D, Weisfelt M, et al. Cognitive outcome in adults after bacterial meningitis. J Neurol Neurosurg Psychiatry 2007; 78:1092-1096.
3. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849-1859.
4. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010; 23:467-492.
5. McIntyre PB, O'Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet 2012; 380:1703-1711.
6. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011; 364:2016-2025.
7. van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet 2012; 380:1693-1702.
8. Scarborough M, Thwaites GE. The diagnosis and management of acute bacterial meningitis in resource-poor settings. Lancet Neurol 2008; 7:637-648.
9. Scarborough M, Gordon SB, Whitty CJ, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007; 357:2441-2450. (Pubitemid 350272783)
10. Ajdukiewicz KM, Cartwright KE, Scarborough M, et al. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis 2011; 11:293-300.
11. Woehrl B, Brouwer MC, Murr C, et al. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest 2011; 121:3943-3953.
12. Adriani KS, Brouwer MC, Geldhoff M, et al. Common polymorphisms in the complement system and susceptibility to bacterial meningitis. J Infect 2013; 66:255-262.
13. Adriani KS, Brouwer MC, Baas F, et al. Genetic variation in the beta2-adrenocepter gene is associated with susceptibility to bacterial meningitis in adults. PLoS One 2012; 7:e37618.
14. Brouwer MC, van der Ende A, Baas F, van de Beek D. Genetic variation in GLCCI1 and dexamethasone in bacterial meningitis. J Infect 2012; 65:465-467.
15. van Well GT, Sanders MS, Ouburg S, et al. Polymorphisms in Toll-like receptors 2, 4, and 9 are highly associated with hearing loss in survivors of bacterial meningitis. PLoS One 2012; 7:e35837.
16. Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005; 366:144-150. (Pubitemid 40991215)
17. International Vaccine Access Center. VIMS Report: Global Vaccine Introduction. 2012.
18. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13:302-317. (Pubitemid 30205428)
19. Kisakye A, Makumbi I, Nansera D, et al. Surveillance for Streptococcus pneumoniae meningitis in children aged
20. Traore Y, Tameklo TA, Njanpop-Lafourcade BM, et al. Incidence, seasonality, age distribution, and mortality of pneumococcal meningitis in Burkina Faso and Togo. Clin Infect Dis 2009; 48 (Suppl 2):S181-S189.
21. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010; 7.
22. Artenstein AW, Laforce FM. Critical episodes in the understanding and control of epidemic meningococcal meningitis. Vaccine 2012; 30:4701-4707.
23. Decosas J, Koama JB. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2002; 2:763-765. (Pubitemid 35434562)
24. Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012; 30S:B26-B36.
25. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511-1520.
26. Heckenberg SG, Brouwer MC, van der Ende A, van de Beek D. Adjunctive dexamethasone in adults with meningococcal meningitis. Neurology 2012; 79:1563-1569.
27. Novak RT, Kambou JL, Diomande FV, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012; 12:757-764.
28. Kristiansen PA, Diomande F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013; 56:354-363.
29. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379:617-624.
30. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. J Am Med Assoc 2012; 307:573-582.
31. van de Beek D. The burden of serogroup B meningococcal disease. Lancet Neurol 2012; 11:743-745.
32. van de Beek D. Progress and challenges in bacterial meningitis. Lancet 2012; 380:1623-1624.
33. Brouwer MC, Thwaites GE, Tunkel AR, van de Beek D. Dilemmas in the diagnosis of acute community-acquired bacterial meningitis. Lancet 2012; 380:1684-1692.
34. Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009; 37:2071-2078.
35. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013; 56:236-244.
36. Pelkonen T, Roine I, Cruzeiro ML, et al. Slow initial beta-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infect Dis 2011; 11:613-621.
37. Molyneux E, Nizami SQ, Saha S, et al. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet 2011; 377:1837-1845.
38. U.S. National Institutes of Health, trial register. http://www. clinicaltrials.gov.
39. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267-1284. (Pubitemid 39458512)
40. Visintin C, Mugglestone MA, Fields EJ, et al. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance. Br Med J 2010; 340:c3209.
41. Snape MD, Kelly DF. Fine with five? Shorter antibiotic courses for childhood meningitis. Lancet 2011; 377:1809-1810.
42. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549-1556. (Pubitemid 35315835)
43. Fritz D, Brouwer MC, van de Beek D. Dexamethasone and long-term survival in bacterial meningitis. Neurology 2012; 79:2177-2179.
44. Weisfelt M, Hoogman M, van de Beek D, et al. Dexamethasone and long-term outcome in adults with bacterial meningitis. Ann Neurol 2006; 60:456-468. (Pubitemid 44684982)
45. Nguyen TH, Tran TH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med 2007; 357:2431-2440. (Pubitemid 350272782)
46. Molyneux EM, Walsh AL, Forsyth H, et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet 2002; 360:211-218. (Pubitemid 34804649)
47. Peltola H, Roine I, Fernandez J, et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2007; 45:1277-1286. (Pubitemid 351411900)
48. van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 2010; 9:254-263.
49. Brouwer MC, McIntyre P, de Gans J, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2010; 9:CD004405.
50. Fitch MT, van de Beek D. Drug insight: steroids in CNS infectious diseases: new indications for an old therapy. Nat Clin Pract Neurol 2008; 4:97-104. (Pubitemid 351248067)
51. Brouwer MC, Heckenberg SG, de Gans J, et al. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology 2010; 75:1533-1539.
52. Blaser C, Klein M, Grandgirard D, et al. Adjuvant glycerol is not beneficial in experimental pneumococcal meningitis. BMC Infect Dis 2010; 10:84.
53. Saez-Llorens X, McCracken GH Jr. Glycerol and bacterial meningitis. Clin Infect Dis 2007; 45:1287-1289. (Pubitemid 351411901)
54. Kuikka A, Sivonen A, Emelianova A, Valtonen VV. Prognostic factors associated with improved outcome of Escherichia coli bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1997; 16:125-134. (Pubitemid 27135963)
55. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17:701-708. (Pubitemid 29218992)
56. Angstwurm K, Reuss S, Freyer D, et al. Induced hypothermia in experimental pneumococcal meningitis. J Cereb Blood Flow Metab 2000; 20:834-838. (Pubitemid 30317058)
57. Lepur D, Kutlesa M, Barsic B. Induced hypothermia in adult communityacquired bacterial meningitis: more than just a possibility? J Infect 2011; 62:172-177.
58. Petersen L, Andersen PK, Sorensen TI. Genetic influences on incidence and case-fatality of infectious disease. PLoS One 2010; 5:e10603.
59. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318:727-732. (Pubitemid 18090256)
60. Brouwer MC, de Gans J, Heckenberg SG, et al. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and metaanalysis. Lancet Infect Dis 2009; 9:31-44.
61. Brouwer MC, Read RC, van de Beek D. Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:262-274.
62. Chapman SJ, Hill AV. Human genetic susceptibility to infectious disease. Nat Rev Genet 2012; 13:175-188.
63. Sanders MS, van Well GT, Ouburg S, et al. Single nucleotide polymorphisms in TLR9 are highly associated with susceptibility to bacterial meningitis in children. Clin Infect Dis 2011; 52:475-480.
64. Vardar F, Pehlivan S, Onay H, et al. Association between mannose binding lectin polymorphisms and predisposition to bacterial meningitis. Turk J Pediatr 2007; 49:270-273. (Pubitemid 47554896)
65. Doernberg S, Schaaf B, Dalhoff K, et al. Association of macrophage migration inhibitory factor (MIF) polymorphisms with risk of meningitis from Streptococcus pneumoniae. Cytokine 2011; 53:292-294.
66. Geldhoff M, Mook-Kanamori BB, Brouwer MC, et al. Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis. Immunogenetics 2013; 65:9-16.
67. Maller JB, Fagerness JA, Reynolds RC, et al. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet 2007; 39:1200-1201. (Pubitemid 47482689)
68. Heurich M, Martinez-Barricarte R, Francis NJ, et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA 2011; 108:8761-8766.
69. Coureuil M, Lecuyer H, Scott MG, et al. Meningococcus hijacks a beta2-adrenoceptor/beta-Arrestin pathway to cross brain microvasculature endothelium. Cell 2010; 143:1149-1160.
70. Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011; 365:1173-1183.
71. Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev 2011; 24:557-591.
72. Hoegen T, Tremel N, Klein M, et al. The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release. J Immunol 2011; 187:5440-5451.